Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head

Cancer of the Pancreatic Head Clinical Trial

Official title: Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head

Status Completed

Clinical Trial Summary

Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head.

Clinical Trial Description

Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head. Two cycles of chemotherapy are given on day 1 and 15 each. After restaging excludes disease progression, a standard Whipple procedure is performed.

Staging and restaging procedures include abdominal CT, diagnostic laparoscopy, PET/CT, tumor markers (CEA, CA 19-9) and assessment of the quality of life by the QLQ-30.

• Trial with medicinal product ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cancer of the Pancreatic Head

• NCT number: NCT00490360
• Study type: Interventional
• Source: University of Zurich
• Status: Completed
• Phase: Phase 2
• Start date: October 2001
• Completion date: May 2007